Cns Pharmaceuticals, INC

CNS Pharmaceuticals announces a strategic pivot towards oncology and neurology, bolstered by a $22.5 million financing round and a new executive team.

CNS Pharmaceuticals, Inc. announced a $22.5 million private placement of common stock and pre-funded warrants to institutional investors.

CNS Pharmaceuticals, Inc. announced the appointment of Dr. Lynne Kelley as its new Chief Medical Officer, effective March 2, 2026, following the separation of Dr. Sandra Silberman.

CNS Pharmaceuticals, Inc. announced the appointment of Steve OLoughlin as its new Chief Financial Officer, effective March 2, 2026, with current CFO Christopher Downs transitioning to Senior Vice President Finance.

CNS Pharmaceuticals, Inc. announced the appointment of Rami Levin as its new Chief Executive Officer and President, effective January 1, 2026, following the resignation of John Climaco.

CNS Pharmaceuticals' stockholders approved a significant increase in authorized common and preferred shares and expanded its 2020 Equity Plan.

CNS Pharmaceuticals reported a net loss of $4.94 million for Q1 2026, an increase from the prior year, alongside a strategic shift towards new therapies and out-licensing legacy assets.

CNS Pharmaceuticals reported a reduced net loss and increased cash, but its Berubicin trial failed to meet its primary endpoint, shifting focus to TPI 287 development.

CNS Pharmaceuticals reported an increased net loss for the first half of 2025 and revealed its Berubicin trial did not meet its primary overall survival endpoint, despite successful capital raises.

CNS Pharmaceuticals' Q1 2025 results show increased R&D spending and a net loss, with the company evaluating paths forward for Berubicin and focusing on TPI 287 development.

CNS Pharmaceuticals reported a net loss of $11.7 million for the nine months ended September 30, 2024, while continuing to advance its clinical trial for Berubicin and securing new licensing agreements.

CNS Pharmaceuticals reported its second quarter 2024 financial results, highlighting ongoing clinical trial progress and recent capital raising activities.

CNS Pharmaceuticals, Inc. filed an amendment to its 2025 Annual Report to provide required disclosures regarding directors, executive compensation, and corporate governance.

CNS Pharmaceuticals files an amendment to its 2024 annual report on Form 10-K to include information required by Items 10 through 14 of Part III, which were initially omitted.

CNS Pharmaceuticals' 10-K filing reveals a year of strategic shifts, focusing on TPI 287 development and analyzing the path forward after topline data from the Berubicin trial did not meet its primary endpoint.

CNS Pharmaceuticals' 2023 annual report details ongoing clinical trials for Berubicin, financial losses, and the need for substantial future funding.

CNS Pharmaceuticals, Inc. director Faith Charles has granted a power of attorney to Rami Levin and Steve O'Loughlin for SEC filing compliance.

CNS Pharmaceuticals' Chief Technology Officer, Eric Faulkner, received a grant of 9,500 Restricted Stock Units as part of his employment compensation.

CNS Pharmaceuticals, Inc. Chief Financial Officer Steve O'Loughlin received a grant of 9,500 restricted stock units as part of his employment compensation.

CNS Pharmaceuticals' CEO and President, Rami Levin, was granted 19,000 restricted stock units, vesting over several years, as part of his employment.

CNS Pharmaceuticals Director Jeffry R. Keyes was granted 1,517 stock options with an exercise price of $12.48, vesting quarterly over one year.

CNS Pharmaceuticals Director Bettina M. Cockroft was granted 1,517 stock options with an exercise price of $12.48, vesting quarterly over one year.

CNS Pharmaceuticals, Inc. filed a supplement to its proxy statement to correct an error on the proxy card related to the 'say-on-pay' frequency vote for its upcoming November 17, 2025 annual meeting.

CNS Pharmaceuticals, Inc. will hold its Annual Meeting on November 17, 2025, seeking stockholder approval for key proposals including a significant increase in authorized shares and re-election of directors.

CNS Pharmaceuticals has amended its reverse stock split proposal to provide cash payments instead of fractional shares to stockholders.

CNS Pharmaceuticals is holding a special meeting to seek stockholder approval for a reverse stock split and warrant repricing to comply with Nasdaq listing requirements.

CNS Pharmaceuticals is asking stockholders to approve several key proposals at its upcoming annual meeting, including a reverse stock split, an increase in authorized shares, and the repricing of certain warrants.

CNS Pharmaceuticals launches an offering of common stock and warrants aiming to raise up to $7 million for working capital and general corporate purposes.

CNS Pharmaceuticals plans to offer shares of common stock, pre-funded warrants, and Series F warrants in a best-efforts offering.

CNS Pharmaceuticals is undertaking a public offering to raise capital for its CNS-201 trial, other research and development, and working capital.

CNS Pharmaceuticals has filed a registration statement for the resale of up to 2,359,000 shares of its common stock issuable upon the exercise of outstanding warrants held by selling shareholders.

CNS Pharmaceuticals is launching a securities offering to raise up to $30 million, primarily to fund its CNS-201 trial for Glioblastoma.

CNS Pharmaceuticals is launching a public offering of common stock, pre-funded warrants, and common warrants to fund its clinical trial and for general corporate purposes.

Stonepine Capital Management has filed a Schedule 13G reporting a 9.9% beneficial ownership stake in CNS Pharmaceuticals, Inc. consisting of common stock and warrants.

Ikarian Capital, LLC and Neil Shahrestani have filed a Schedule 13G reporting a 5.7% beneficial ownership stake in CNS Pharmaceuticals, Inc.

Stonepine Capital Management and affiliates report a 7.9% beneficial ownership stake in CNS Pharmaceuticals, Inc. as of December 31, 2025.

Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in CNS Pharmaceuticals Inc. common stock.

Stonepine Capital Management and its affiliates have reported a 5.6% beneficial ownership stake in CNS Pharmaceuticals, Inc. as of October 29, 2025.

Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in CNS Pharmaceuticals Inc. common stock.